Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Council Recognizes Unmet Medical Need for Off-Label Use of 3 Drugs
May 19, 2017
- Maintain Prices for On-Patent Drugs, Off-Year Revisions Should Only Cover Limited Products: FPMAJ
May 19, 2017
- Lawmakers Hear from EFPIA, Say They Didn’t Know Japan Drug Market Would Shrink
May 19, 2017
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.7%: Chuikyo
May 19, 2017
- MHLW Discussing Restrictions on Prescriptions of Codeine-Containing Medicines to Children
May 19, 2017
- JPWA Calls for Off-Year Surveys Covering All Products: Chuikyo Hearing
May 19, 2017
- JGA Calls for Elimination of Price Bracket Grouping Rule for Listed Generics
May 19, 2017
- Global Headquarters Watching Japan, Keep Drug Prices for Patented Period: PhRMA, EFPIA
May 19, 2017
- Social Security Council Subcommittee Negative about Reference Pricing System
May 18, 2017
- FPMAJ, EFPIA See Need to Revisit Cost-Based Pricing Method: Chuikyo
May 18, 2017
- MHLW Advisory Panel to Review Eli Lilly’s JAK Inhibitor Baricitinib on May 30
May 18, 2017
- (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
- MHLW Study Group to Issue Report Calling for Guidelines to Promote Efficient Development of Biosimilars
May 18, 2017
- Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May 17, 2017
- Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May 17, 2017
- 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
- Ninlaro, 7 Other Drugs OK’ed for Reimbursement Listing on May 24
May 17, 2017
- Japan, South Korea Set Up Working Groups to Collaborate on Harmonization
May 16, 2017
- Procedures for Providing Unapproved Drugs to Developing Countries in Emergencies Could Become Finalized in June
May 15, 2017
- Transition Period of “at Least 1 Year” Needed for New Package Insert Format: MHLW
May 11, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…